Kamal Pohar, MD

Li R.; Hensley P.J.; Gupta S.; Al-Ahmadie H.; Babjuk M.; Black P.C.; Brausi M.; Bree K.K.; Fernández M.I.; Guo C.C.; Horowitz A.; Lamm D.L.; Lerner S.P.; Lotan Y.; Mariappan P.; McConkey D.; Mertens L.S.; Mir C.; Ross J.S.; O'Donnell M.; Palou J.; Pohar K.; Steinberg G.; Soloway M.; Spiess P.E.; Svatek R.S.; Tan W.S.; Taoka R.; Buckley R.; Kamat A.M. 12-01-2024. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer European Urology, 86 6, 516-527

Soltani-Tehrani A.M.; Kumar A.; Pohar K.S. 11-30-2024. Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer Translational Cancer Research, 13 11, 6489-6502

Dangle P.; Wang W.; Pohar K. 11-11-2008. Inflammatory myofibroblastic tumor of epididymis: A case report and review of literature World Journal of Surgical Oncology, 6 ,

Dangle P.; Zaharieva B.; Jia H.; Pohar K. 11-02-2009. Ras-MAPK pathway as a therapeutic target in cancer - Emphasis on bladder cancer Recent Patents on Anti Cancer Drug Discovery, 4 2, 125-136

Soria F.; D'Andrea D.; Pohar K.; Shariat S.F.; Lotan Y. 11-01-2018. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: Any ro Current Opinion in Urology, 28 6, 577-583

Lerner S.P.; Tangen C.; Svatek R.S.; Daneshmand S.; Pohar K.S.; Skinner E.; Schuckman A.; Sagalowsky A.I.; Smith N.D.; Kamat A.M.; Kassouf W.; Plets M.; Bangs R.; Koppie T.M.; Alva A.; La Rosa F.G.; Pal S.K.; Kibel A.S.; Canter D.J.; Thompson I.M. 10-03-2024. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer New England Journal of Medicine, 391 13, 1206-1216

Schafer J.M.; Song N.J.; Xiao T.; Gauntner T.D.; Jung K.J.; Fitts E.G.; Kumar K.; Jeon H.S.; Elaoud R.A.; Reynolds K.; Caruso V.M.; Levin T.G.; McConkey D.; Lee C.T.; Pohar K.S.; Clinton S.K.; Carson W.; Chung D.; Li Z.; Sundi D. 10-02-2025. T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunol Journal for Immunotherapy of Cancer, 13 10,

Nguyen H.T.; Shah Z.K.; Mortazavi A.; Pohar K.S.; Wei L.; Zynger D.L.; Knopp M.V. 10-01-2019. Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve Medicine, 98 42, e17075

Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Clark P.E.; Downs T.M.; Efstathiou J.A.; Flaig T.W.; Friedlander T.; Greenberg R.E.; Guru K.A.; Hahn N.; Herr H.W.; Hoimes C.; Inman B.A.; Jimbo M.; Kader A.K.; Lele S.M.; Meeks J.J.; Michalski J.; Montgomery J.S.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Porter M.P.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Sonpavde G.; Tward J.; Wile G.; Dwyer M.A.; Gurski L.A. 10-01-2017. Bladder cancer, version 5.2017: Clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network, 15 10, 1240-1267

Clark P.E.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Efstathiou J.A.; Flaig T.W.; Friedlander T.; Greenberg R.E.; Guru K.A.; Hahn N.; Herr H.W.; Hoimes C.; Inman B.A.; Kader A.K.; Kibel A.S.; Kuzel T.M.; Lele S.M.; Meeks J.J.; Michalski J.; Montgomery J.S.; Pagliaro L.C.; Pal S.K.; Patterson A.; Petrylak D.; Plimack E.R.; Pohar K.S.; Porter M.P.; Sexton W.J.; Siefker-Radtke A.O.; Sonpavde G.; Tward J.; Wile G.; Dwyer M.A.; Smith C. 10-01-2016. Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines Jnccn Journal of the National Comprehensive Cancer Network, 14 10, 1213-1224

D'Souza A.M.; Pohar K.S.; Arif T.; Geyer S.; Zynger D.L. 10-01-2012. Retrospective analysis of survival in muscle-invasive bladder cancer: Impact of pT classification, n Virchows Archiv, 461 4, 467-474

Pohar K.; Rabbani F.; Bosl G.; Motzer R.; Bajorin D.; Sheinfeld J. 10-01-2003. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinom Journal of Urology, 170 4 I, 1155-1158

Chang E.; Hahn N.M.; Lerner S.P.; Fallah J.; Agrawal S.; Kamat A.M.; Bhatnagar V.; Svatek R.S.; Jaigirdar A.A.; Bross P.; Shore N.; Kates M.; Sachse K.; Brewer J.R.; O'donnell M.A.; Steinberg G.D.; Viviano C.J.; Bloomquist E.; Ribal M.J.; Galsky M.D.; Oliver R.; Black P.C.; Al-Ahmadie H.; Brothers K.; Pohar K.; Dinney C.P.; Feng Z.; Downs T.M.; Porten S.P.; Smith A.B.; Bangs R.; Psutka S.P.; Agarwal N.; Amiri-Kordestani L.; Suzman D.L.; Pazdur R.; Kluetz P.G.; Weinstock C. 09-25-2023. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer Bladder Cancer, 9 3, 271-286

Chandra M.; Li R.; Parwani A.; Carson W.E.; Pohar K.; Sundi D. 09-01-2023. Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients’ access to novel th Urologic Oncology Seminars and Original Investigations, 41 9, 390-390.e17

Flaig T.W.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Downs T.M.; Efstathiou J.A.; Friedlander T.; Greenberg R.E.; Guru K.A.; Hahn N.; Herr H.W.; Hoimes C.; Inman B.A.; Jimbo M.; Kader A.K.; Lele S.M.; Meeks J.J.; Michalski J.; Montgomery J.S.; Pagliaro L.C.; Pal S.K.; Patterson A.; Petrylak D.P.; Plimack E.R.; Pohar K.S.; Porter M.P.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Tward J.; Wile G.; Johnson-Chilla A.; Dwyer M.A.; Gurski L.A. 09-01-2018. NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines Jnccn Journal of the National Comprehensive Cancer Network, 16 9, 1041-1053

Shen H.M.; D'Souza A.M.; Green I.F.; Pohar K.S.; Mortazavi A.; Zynger D.L. 09-01-2015. Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chem Human Pathology, 46 9, 1367-1375

Pohar K. 09-01-2013. The anatomic extent and completeness of pelvic lymphadenectomy is what matters Current Opinion in Urology, 23 5, 444-448

Korytko T.; Lowe G.; Jimenez R.; Pohar K.; Martin D. 09-01-2012. Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma re Urologic Oncology Seminars and Original Investigations, 30 5, 602-606

Chapman D.; Pohar K.; Gong M.; Bahnson R. 09-01-2009. Preoperative hydronephrosis as an indicator of survival after radical cystectomy Urologic Oncology Seminars and Original Investigations, 27 5, 491-495

Shah K.; Pohar K. 09-01-2007. State-of-the-art surgical management of testicular tumors Expert Review of Anticancer Therapy, 7 9, 1301-1308

Grainger E.M.; Hadley C.W.; Moran N.E.; Riedl K.M.; Gong M.C.; Pohar K.; Schwartz S.J.; Clinton S.K. 08-28-2015. A comparison of plasma and prostate lycopene in response to typical servings of tomato soup, sauce o British Journal of Nutrition, 114 4, 596-607

Flaig T.W.; Spiess P.E.; Abern M.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Chan K.; Chang S.; Friedlander T.; Greenberg R.E.; Guru K.A.; Herr H.W.; Hoffman-Censits J.; Kishan A.; Kundu S.; Lele S.M.; Mamtani R.; Margulis V.; Mian O.Y.; Michalski J.; Montgomery J.S.; Nandagopal L.; Pagliaro L.C.; Parikh M.; Patterson A.; Plimack E.R.; Pohar K.S.; Preston M.A.; Richards K.; Sexton W.J.; Siefker-Radtke A.O.; Tollefson M.; Tward J.; Wright J.L.; Dwyer M.A.; Cassara C.J.; Gurski L.A. 08-01-2022. Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines Jnccn Journal of the National Comprehensive Cancer Network, 20 8, 866-878

Pohar K.S.; Patel S.; Lotan Y.; Trabulsi E.; Woods M.; Downs T.; Huang W.C.; Jones J.; Taylor J.; O'Donnell M.; Bivalacqua T.J.; DeCastro J.; Steinberg G.; Kamat A.M.; Resnick M.J.; Konety B.; Schoenberg M.; Jones J.S.; Daneshmand S. 08-01-2022. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder ca Urologic Oncology Seminars and Original Investigations, 40 8, 382-382.e6

Daneshmand S.; Bazargani S.T.; Bivalacqua T.J.; Holzbeierlein J.M.; Willard B.; Taylor J.M.; Liao J.C.; Pohar K.; Tierney J.; Konety B. 08-01-2018. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicent Urologic Oncology Seminars and Original Investigations, 36 8, 361-361.e6

Kent L.N.; Rakijas J.B.; Pandit S.K.; Westendorp B.; Chen H.Z.; Huntington J.T.; Tang X.; Bae S.; Srivastava A.; Senapati S.; Koivisto C.; Martin C.K.; Cuitino M.C.; Perez M.; Clouse J.M.; Chokshi V.; Shinde N.; Kladney R.; Sun D.; Perez-Castro A.; Matondo R.B.; Nantasanti S.; Mokry M.; Huang K.; Machiraju R.; Fernandez S.; Rosol T.J.; Coppola V.; Pohar K.S.; Pipas J.M.; Schmidt C.R.; De Bruin A.; Leone G. 08-01-2016. E2f8 mediates tumor suppression in postnatal liver development Journal of Clinical Investigation, 126 8, 2955-2969

Ahmadi H.; Ladi-Seyedian S.S.; Konety B.; Pohar K.; Holzbeierlein J.M.; Kates M.; Willard B.; Taylor J.M.; Liao J.C.; Kaimakliotis H.Z.; Porten S.P.; Steinberg G.D.; Tyson M.D.; Lotan Y.; Daneshmand S. 07-01-2022. Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional BJU International, 130 1, 62-67

Daneshmand S.; Brummelhuis I.S.G.; Pohar K.S.; Steinberg G.D.; Aron M.; Cutie C.J.; Keegan K.A.; Maffeo J.C.; Reynolds D.L.; Raybold B.; Chau A.; Witjes J.A. 07-01-2022. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery syste Urologic Oncology Seminars and Original Investigations, 40 7, 344-344.e9

Li R.X.; Li X.L.; Li Z.; Jiao Y.; Zhao Z.G.; Wang H.; Zhang B.; Jia H.T.; Pohar K. 06-28-2016. Transcription factors E2F3 regulates cytokine response in invasive bladder cancer Chinese Journal of Cancer Prevention and Treatment, 23 12, 768-793

Inman B.A.; Hahn N.M.; Stratton K.; Kopp R.; Sankin A.; Skinner E.; Pohar K.; Gartrell B.A.; Pham S.; Rishipathak D.; Mariathasan S.; Davarpanah N.; Carter C.; Steinberg G.D. 06-01-2023. A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-ris European Urology Oncology, 6 3, 313-320

Lotan Y.; Bivalacqua T.J.; Downs T.; Huang W.; Jones J.; Kamat A.M.; Konety B.; Malmström P.U.; McKiernan J.; O’Donnell M.; Patel S.; Pohar K.; Resnick M.; Sankin A.; Smith A.; Steinberg G.; Trabulsi E.; Woods M.; Daneshmand S. 06-01-2019. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review Nature Reviews Urology, 16 6, 377-386

Williams S.B.; Kamat A.M.; Chamie K.; Froehner M.; Wirth M.P.; Wiklund P.N.; Black P.C.; Steinberg G.D.; Boorjian S.A.; Daneshmand S.; Goebell P.J.; Pohar K.S.; Shariat S.F.; Thalmann G.N. 06-01-2018. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients European Urology Oncology, 1 2, 91-100

Hussein A.A.; Hinata N.; Dibaj S.; May P.R.; Kozlowski J.D.; Abol-Enein H.; Abaza R.; Eun D.; Khan M.S.; Mohler J.L.; Agarwal P.; Pohar K.; Sarle R.; Boris R.; Mane S.S.; Hutson A.; Guru K.A. 06-01-2017. Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion BJU International, 119 6, 879-884

Pohar K.S. 05-01-2020. Blue Light Cystoscopy: Indications and Outcomes Current Urology Reports, 21 5,

Daneshmand S.; Patel S.; Lotan Y.; Pohar K.; Trabulsi E.; Woods M.; Downs T.; Huang W.; Jones J.; O'Donnell M.; Bivalacqua T.; DeCastro J.; Steinberg G.; Kamat A.; Resnick M.; Konety B.; Schoenberg M.; Jones J.S.; Bazargani S.; Djaladat H.; Schuckman A.; Cookson M.; Cross B.; Stratton K.; Lallas C.D.; Gomella L.; Mann M.; Johnson M.; Pierorazio P.; McKiernan J.; Wenske S.; Sankin A.; Merrill M.; Shabsigh A.; Nielsen M.; Pruthi R.; Smith A.; Shah J.B.; Taylor J.; Weight C. 05-01-2018. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Journal of Urology, 199 5, 1158-1165

Nguyen H.T.; Shah Z.K.; Mortazavi A.; Pohar K.S.; Wei L.; Jia G.; Zynger D.L.; Knopp M.V. 05-01-2017. Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant European Radiology, 27 5, 2146-2152

Nguyen H.T.; Jia G.; Shah Z.K.; Pohar K.; Mortazavi A.; Zynger D.L.; Wei L.; Yang X.; Clark D.; Knopp M.V. 05-01-2015. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contra Journal of Magnetic Resonance Imaging, 41 5, 1374-1382

Clark P.E.; Spiess P.E.; Agarwal N.; Biagioli M.C.; Eisenberger M.A.; Greenberg R.E.; Herr H.W.; Inman B.A.; Kuban D.A.; Kuzel T.M.; Lele S.M.; Michalski J.; Pagliaro L.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Porter M.P.; Richie J.P.; Sexton W.J.; Shipley W.U.; Small E.J.; Trump D.L.; Wile G.; Wilson T.G.; Dwyer M.; Ho M. 05-01-2013. Penile cancer Jnccn Journal of the National Comprehensive Cancer Network, 11 5, 594-615

Pohar K.; Gong M.; Bahnson R.; Miller E.; Clinton S. 05-01-2003. Tomatoes, lycopene and prostate cancer: A clinician's guide for counseling those at risk for prostat World Journal of Urology, 21 1, 9-14

Lavery H.; Zaharieva B.; McFaddin A.; Heerema N.; Pohar K. 04-07-2017. A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection BMC Cancer, 17 1,

Gore J.L.; Follmer K.; Reynolds J.; Nash M.; Anderson C.B.; Catto J.W.F.; Chamie K.; Daneshmand S.; Dickstein R.; Garg T.; Gilbert S.M.; Guzzo T.J.; Kamat A.M.; Kates M.R.; Lane B.R.; Lotan Y.; Mansour A.M.; Master V.A.; Montgomery J.S.; Morris D.S.; Nepple K.G.; O'Neil B.B.; Patel S.; Pohar K.; Porten S.P.; Riggs S.B.; Sankin A.; Scarpato K.R.; Shore N.D.; Steinberg G.D.; Strope S.A.; Taylor J.M.; Comstock B.A.; Kessler L.G.; Wolff E.M.; Smith A.B. 04-01-2024. Interruptions in bladder cancer care during the COVID-19 public health emergency Urologic Oncology Seminars and Original Investigations, 42 4, 116-116.e21

Ladi-Seyedian S.S.; Ghoreifi A.; Konety B.; Pohar K.; Holzbeierlein J.M.; Taylor J.; Kates M.; Willard B.; Taylor J.M.; Liao J.C.; Kaimakliotis H.Z.; Porten S.P.; Steinberg G.D.; Tyson M.D.; Lotan Y.; Daneshmand S. 04-01-2024. Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights fro Cancers, 16 7,

Clark P.E.; Agarwal N.; Biagioli M.C.; Eisenberger M.A.; Greenberg R.E.; Herr H.W.; Inman B.A.; Kuban D.A.; Kuzel T.M.; Lele S.M.; Michalski J.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Porter M.P.; Richie J.P.; Sexton W.J.; Shipley W.U.; Small E.J.; Spiess P.E.; Trump D.L.; Wile G.; Wilson T.G.; Dwyer M.; Ho M. 04-01-2013. Bladder cancer: Clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network, 11 4, 446-475

Perrino C.; Pohar K.; Zynger D. 04-01-2012. Urinary bladder chondroma Virchows Archiv, 460 4, 437-438

Esteller M.; Cordon-Cardo C.; Corn P.G.; Meltzer S.J.; Pohar K.S.; Watkins D.N.; Capella G.; Peinado M.A.; Matias-Guiu X.; Prat J.; Baylin S.B.; Herman J.G. 04-01-2001. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2 Cancer Research, 61 7, 2816-2821

Chappidi M.R.; Yang H.; Meng M.V.; Bivalacqua T.J.; Daneshmand S.; Holzbeierlein J.M.; Kaimakliotis H.Z.; Konety B.; Liao J.C.; Pohar K.; Steinberg G.D.; Taylor J.M.; Tyson M.D.; Willard B.; Lotan Y.; Porten S.P.; Kates M. 03-01-2022. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detecti Journal of Urology, 207 3, 534-540

Kent L.N.; Bae S.; Tsai S.Y.; Tang X.; Srivastava A.; Koivisto C.; Martin C.K.; Ridolfi E.; Miller G.C.; Zorko S.M.; Plevris E.; Hadjiyannis Y.; Perez M.; Nolan E.; Kladney R.; Westendorp B.; De Bruin A.; Fernandez S.; Rosol T.J.; Pohar K.S.; Pipas J.M.; Leone G. 03-01-2017. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma Journal of Clinical Investigation, 127 3, 830-842

Tretter E.; Ebel J.; Pohar K.; Zynger D. 03-01-2017. Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer? Human Pathology, 61 , 190-198

Gore J.L.; Wolff E.M.; Nash M.G.; Comstock B.A.; Gilbert S.M.; Chang S.S.; Chisolm S.; MacLean D.B.; Wright J.L.; Kates M.R.; Pohar K.S.; Guzzo T.J.; Bivalacqua T.J.; Nepple K.G.; Montgomery J.S.; Scarpato K.R.; Woldu S.L.; Master V.A.; Chen D.Y.T.; Mossanen M.; Daneshmand S.; O'Neil B.B.; Tyson M.D.; Westerman M.E.; Kamat A.M.; Mansour A.M.; Chamie K.; Riggs S.B.; Kukreja J.B.; Modi P.K.; Garg T.; Peyton C.C.; Nix J.W.; Dickstein R.; Gadzinski A.J.; Sankin A.; Shore N.D.; Lane B.R.; Bassett J.C.; Patel S.; Morris D.S.; Macleod L.C.; Lee E.K.; Ritch C.R.; Follmer K.M.; Lee J.R.; Kim S.M.; Kessler L.G.; Smith A.B. 02-01-2026. Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therap Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 44 4, 274-285

Sundi D.; Collier K.A.; Yang Y.; Diaz D.A.; Pohar K.S.; Singer E.A.; Gupta S.; Carson W.E.; Clinton S.K.; Li Z.; Messing E.M. 02-01-2024. Roles of Androgen Receptor Signaling in Urothelial Carcinoma Cancers, 16 4,

Alsyouf M.; Ladi-Seyedian S.S.; Konety B.; Pohar K.; Holzbeierlein J.M.; Kates M.; Willard B.; Taylor J.M.; Liao J.C.; Kaimakliotis H.Z.; Porten S.P.; Steinberg G.D.; Tyson M.D.; Lotan Y.; Daneshmand S. 02-01-2023. Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light Urologic Oncology Seminars and Original Investigations, 41 2, 109-109.e14

Dangle P.; Gong M.; Bahnson R.; Pohar K. 02-01-2010. How Do Commonly Performed Lymphadenectomy Templates Influence Bladder Cancer Nodal Stage? Journal of Urology, 183 2, 499-504

Stout T.E.; Regmi S.K.; Daneshmand S.; Porten S.P.; Pohar K.S.; Konety B.R. 01-01-2022. Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Pros Urology Practice, 9 1, 94-99

Pohar K.S. 01-01-2021. Cystoscopy and Enhanced Diagnostics Bladder Cancer A Practical Guide, , 9-20

Flaig T.W.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Chang S.; Downs T.M.; Efstathiou J.A.; Friedlander T.; Greenberg R.E.; Guru K.A.; Guzzo T.; Herr H.W.; Hoffman-Censits J.; Hoimes C.; Inman B.A.; Jimbo M.; Karim Kader A.; Lele S.M.; Michalski J.; Montgomery J.S.; Nandagopal L.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Tward J.; Wright J.L.; Gurski L.A.; Johnson-Chilla A. 01-01-2020. Bladder cancer, version 3.2020 Jnccn Journal of the National Comprehensive Cancer Network, 18 2, 329-354

Smith A.B.; Daneshmand S.; Patel S.; Pohar K.; Trabulsi E.; Woods M.; Downs T.; Huang W.; Taylor J.; Jones J.; O'Donnell M.; Bivalacqua T.; DeCastro J.; Steinberg G.; Kamat A.; Resnick M.; Konety B.; Schoenberg M.; Jones J.S.; Lotan Y. 01-01-2019. Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveilla BJU International, 123 1, 35-41

Nguyen H.T.; Mortazavi A.; Pohar K.S.; Zynger D.L.; Wei L.; Shah Z.K.; Jiaa G.; Knopp M.V. 01-01-2017. Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Bladder Cancer, 3 4, 237-244

Pohar K.S.; Smith N.D. 01-01-2015. Management of the urethra in the cystectomy patient Bladder Cancer Diagnosis and Clinical Management, , 184-189

Calhoun A.N.; Pohar K.S. 01-01-2014. Guideline-Based Management of Muscle-Invasive Bladder Cancer: NCCN, ICUD, and EAU Management of Bladder Cancer A Comprehensive Text with Clinical Scenarios, , 457-463

Daneshmand S.; Schuckman A.K.; Bochner B.H.; Cookson M.S.; Downs T.M.; Gomella L.G.; Grossman H.B.; Kamat A.M.; Konety B.R.; Lee C.T.; Pohar K.S.; Pruthi R.S.; Resnick M.J.; Smith N.D.; Witjes J.A.; Schoenberg M.P.; Steinberg G.D. 01-01-2014. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: Review of the clinic Nature Reviews Urology, 11 10, 589-596

Nguyen H.T.; Pohar K.S.; Jia G.; Shah Z.K.; Mortazavi A.; Zynger D.L.; Wei L.; Clark D.; Yang X.; Knopp M.V. 01-01-2014. Improving bladder cancer imaging using 3-t functional dynamic contrast-enhanced magnetic resonance i Investigative Radiology, 49 6, 390-395

D'Souza A.M.; Phillips G.S.; Pohar K.S.; Zynger D.L. 01-01-2013. Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the Virchows Archiv, 463 6, 811-818

Perrino C.M.; Fichtenbaum E.J.; Pohar K.S.; Zynger D.L. 01-01-2013. Challenges in the pathological reporting of urothelial carcinoma involving prostatic transurethral r Pathology, 45 7, 664-669

Abaza R.; Dangle P.; Gong M.; Bahnson R.; Pohar K. 01-01-2012. Quality of lymphadenectomy is equivalent with robotic and open cystectomy using an extended template Journal of Urology, 187 4, 1200-1205

Dangle P.; Bahnson R.; Pohar K. 01-01-2009. How close are we to establishing standards of lymphadenectomy for invasive bladder cancer? Therapeutic Advances in Urology, 1 3, 167-174

Lavery H.; Bahnson R.; Sharp D.; Pohar K. 01-01-2009. Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors Therapeutic Advances in Urology, 1 4, 199-207

Montie J.E.; Clark P.E.; Eisenberger M.A.; El-Galley R.; Greenberg R.E.; Herr H.W.; Hudes G.R.; Kuban D.A.; Kuzel T.M.; Lange P.H.; Lele S.M.; Michalski J.; Patterson A.; Pohar K.S.; Richie J.P.; Sexton W.J.; Shipley W.U.; Small E.J.; Trump D.L.; Walther P.J.; Wilson T.G. 01-01-2009. Bladder cancer Jnccn Journal of the National Comprehensive Cancer Network, 7 1, 8-38

Cegala D.J.; Bahnson R.R.; Clinton S.K.; David P.; Gong M.C.; Monk J.P.; Nag S.; Pohar K.S. 01-01-2008. Information seeking and satisfaction with physician-patient communication among prostate cancer surv Health Communication, 23 1, 62-69

Dangle P.P.; Wang W.P.; Pohar K.S. 01-01-2008. Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mit Canadian Journal of Urology, 15 5, 4269-4272

Motzer R.J.; Bolger G.B.; Boston B.; Carducci M.A.; Fishman M.; Hancock S.L.; Hauke R.J.; Hudes G.R.; Jonasch E.; Kantoff P.; Kuzel T.M.; Lange P.H.; Levine E.G.; Logothetis C.; Margolin K.A.; Pohar K.; Redman B.G.; Robertson C.N.; Samlowski W.E.; Sheinfeld J. 01-01-2006. Kidney cancer clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network, 4 10, 1072-1081

Motzer R.J.; Bolger G.B.; Boston B.; Carducci M.A.; Fishman M.; Hancock S.L.; Hauke R.J.; Hudes G.R.; Jonasch E.; Kantoff P.; Kuzel T.M.; Lange P.H.; Levine E.G.; Logothetis C.; Margolin K.A.; Pohar K.S.; Redman B.G.; Robertson C.N.; Samlowski W.E.; Sheinfeld J. 01-01-2006. Testicular cancer clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network, 4 10, 1038-1058

Motzer R.J.; Carducci M.A.; Fishman M.; Hancock S.L.; Hauke R.J.; Hudes G.R.; Kantoff P.; Kuzel T.M.; Lange P.H.; Levine E.G.; Logothetis C.; Margolin K.A.; Pili R.; Pohar K.S.; Redman B.G.; Richey S.; Robertson C.N.; Samlowski W.E.; Sheinfeld J.; Urban D.A. 01-01-2005. Kidney cancer: Clinical practice guidelines Jnccn Journal of the National Comprehensive Cancer Network, 3 1, 84-93

Di Como C.J.; Urist M.J.; Babayan I.; Drobnjak M.; Hedvat C.V.; Teruya-Feldstein J.; Pohar K.; Hoos A.; Cordon-Cardo C. 01-01-2002. p63 expression profiles in human normal and tumor tissues Clinical Cancer Research, 8 2, 494-501

Lu M.L.; Charytonowicz E.; Cordon-Cardo C.; Rabbani F.; Dalbagni G.; Pohar K.S.; Wikman F.; Orntoft T.F.; Zhang Z.; Yu G. 01-01-2002. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by c Clinical Cancer Research, 8 1, 171-179

Pohar K.; Sheinfeld J. 01-01-2001. When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter? Journal of Endourology, 15 4, 405-408